However, a gradual tapering off of Semaglutide and starting Tirzepatide can help minimize these effects
Multiple Phase 3 clinical trials in human subjects show sustained weight loss averaging 15-22% of body weight at higher doses, along with major HbA1c reductions, improved glycemic control, visceral fat reduction, and better lipid profiles
True muscle wasting can occur during any form of weight loss if caloric intake, protein, or essential micronutrients are inadequate
Notwithstanding these gains, ~60% of treated animals survived with residual tumor, and immunosuppressive TAM subsets persisted, underscoring the difficulty of fully reprogramming the microenvironment [48]
In light of these concerns surrounding the rising popularity of GLP-1 agonists for weight loss, some key recommendations have emerged: Integrating medications with healthy lifestyle interventions for holistic, long-lasting obesity treatment